After Nepal government approved emergency use of Covishield vaccine, people are hoping the pandemic will falter and human lives would be back on track. Nepal's Department of Drug Administration on Friday issued a release giving information on approving Covishield developed by AstraZeneca and Oxford University, which will be manufactured by Serum Institute of India (SII) in India. Drug regulating authority has also specified Serum Institute of India for importers provided with low cost in purchasing and delivery of vaccine to public. Approving the vaccine for conditional purpose, the department has also asked manufacturers or importers to get approval for registration in order to bring the vaccines. Nepal imposed nationwide and partial lockdown for most of 2020 with rise in imported cases which later took the form of local transmission spreading mostly in urban areas and major cities. The nationwide lockdown which started in March 2020 hampered daily life of people as well as businesses. They now expect to thrive with the approval of vaccine. Though the detailed inoculation plan of Nepal Government is yet to be disclosed, a total of 3 companies applied for approval to take steps forward with Serum Institute for import of vaccines. India has already made conditional emergency approval for Covishield manufactured by the Serum Institute. Being one of the largest producers of vaccines at low cost, India has promised to provide vaccine to its neighbours in near future.
As a new study reveals that a large proportion of doctors and nurses in the United Kingdom have been traumatized by working in ICUs during the coronavirus pandemic, CNN’s Salma Abdelaziz reports from inside the first hotel in the country to have been converted into a overflow hospital to treat patients.
On Day 1 of India's Covid-19 vaccination, two doctors who took the shots shared their experience. Dr Atul Peters and Anil Dhar of Max hospital were given Bharat Biotech's Covaxin and SII-made Covishield jabs respectively. Both didn't experience any side-effects and said that doubts regarding the inoculants are unfounded. Dr Suranjit Chatterjee of Apollo hospital, who is set to receive a shot soon, also weighed in on the controversy regarding Covaxin and its third phase trials. Watch the full video for more.
Credit: HT Digital Content Duration: 08:15Published
The British Red Cross says every Covid death repesents a "colossal loss" across the world, as it expects the global death toll to hit two million on Saturday. Report by Alibhaiz. Like us on Facebook at http://www.facebook.com/itn and follow us on Twitter at http://twitter.com/itn
Puducherry Lieutenant Governor Kiran Bedi called on IAS A. Anbarasu, who has moved on to become Advisor to Administrator, Lakshadweep. Anbarasu worked intensively during COVID-19 pandemic time by coordinating the COVID measures besides other duties assigned to him. Anbarasu belongs to 1996 batch of the Indian Administrative Service (IAS) in the AGMU cadre. While serving in Puducherry he redeemed his duties with great seriousness. While sharing his working experience, Anbarasu said that it was a pleasant experience working under Lieutenant Governor Bedi.
COVID vaccination drive commenced across India on January 16. First vaccination shot of the COVID vaccine in Kolkata Medical College was given to a lady health care worker, Dr. Priyanka Maitra Karwk. She urged people to come forward and take the vaccine. Priyanka Maitra Karwk said, "I am feeling absolutely fine after receiving the vaccine shot. The process is also not painful; it is like any other vaccine. I will take another dose after 28 days. Things look good right now. The minimum risk associated with any vaccine, is associated with this one too, we have to take little bit risk as the disease itself is so profound and deadly. I'd urge people to come up and take the vaccine."
Delhi is in battle mode amid fresh wave of Covid-19 infections. Union Home minister Amit Shah chaired a meeting on countering Covid spike on November 15. Delhi CM Arvind Kejriwal, Union & Delhi Health..
Credit: HT Digital Content Duration: 02:36Published